SciSparc Ltd. (SPRC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders, has announced a non-binding letter of intent to sell its majority stake in MitoCareX Bio for a potential total of $8 million, reflecting a 47% increase in valuation since its initial investment. The transaction, which includes milestone-based increments to the consideration, is aimed at enhancing shareholder value and aligns with SciSparc’s strategic focus on investment and partnership opportunities.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.